Adi Zuloff-Shani
Tracked across 4 events · 35 articles · First seen Jun 18, 2026 · Last active Sep 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: As CEO, Dr. Zuloff-Shani is the public face of the announcement and her leadership is central to the company's strategic progress.
Aug 06, 2026 · 6 articles
Business
Impact: Adi Zuloff-Shani, CEO of Clearmind Medicine, commented on the significance of the patent grants, highlighting their role in advancing clinical programs and reinforcing the company's leadership in psychedelic-based therapies.
Jun 18, 2026 · 7 articles
Tech
Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biopharmaceutical company developing non-hallucinogenic psychedelic-derived neuroplastogens, announced the initiation of Phase IIa, the next stage of its double-blind, placebo-controlled Phase I/IIa clinical trial evaluating CMND-100 for the treatment…
Impact: Adi Zuloff-Shani, Chief Executive Officer of Clearmind, publicly commented on the enrollment milestone, framing it as a major step forward for the program. Her statements help shape investor perception of the company's clinical momentum.
Sep 01, 2026 · 16 articles
Business
Impact: Dr. Adi Zuloff-Shani is the Chief Technology Officer of NeuroThera and commented on the trial initiation, but has no direct financial stake.
Jul 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Adi Zuloff-Shani live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard